The interventional treatment of tricuspid valve disease has evolved in recent years thanks to new research and critical FDA approvals. Cardiologist Ryan Kaple, MD, reviewed this trend for a new video interview.
This type of tracking helps a practice understand how radiologists interact with AI, whether they're appropriately rejecting incorrect results, and if the technology is improving detection of important findings.
Tim Szczykutowicz, PhD, associate professor radiology, University of Wisconsin Madison, explains the new technology developments in GE HealthCare's FDA 510(k)-pending photon-counting CT scanner.
Intravascular lithotripsy is expected to see even wider adoption when lower-profile catheters are introduced and device costs start to drop, explained Samin Sharma, MD.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.
ACC Immediate Past President Cathie Biga spoke to Cardiovascular Business about some of the challenges healthcare faces in the wake of mass layoffs and significant funding cuts put in place by the Trump administration.
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Naples Comprehensive Health is building up what it hopes will be a nationally recognized cardiology program. Robert Cubeddu, MD, and Dee Dee Wang, MD, spoke with Cardiovascular Business about the journey so far.
